TY  - JOUR
AU  - Moreso, Francesc
AU  - Crespo, Marta
AU  - Ruiz, Juan C
AU  - Torres, Armando
AU  - Gutierrez-Dalmau, Alex
AU  - Osuna, Antonio
AU  - Perelló, Manel
AU  - Pascual, Julio
AU  - Torres, Irina B
AU  - Redondo-Pachón, Dolores
AU  - Rodrigo, Emilio
AU  - Lopez-Hoyos, Marcos
AU  - Seron, Daniel
PY  - 2017
DO  - 10.1111/ajt.14520
UR  - http://hdl.handle.net/10668/11613
T2  - American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
AB  - There are no approved treatments for chronic antibody mediated rejection (ABMR). We conducted a multicenter, prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate efficacy and safety of intravenous immunoglobulins (IVIG)...
LA  - en
KW  - clinical research/practice
KW  - clinical trial
KW  - kidney (allograft) function/dysfunction
KW  - kidney transplantation/nephrology
KW  - pathology/histopathology
KW  - rejection: antibody-mediated (ABMR)
KW  - Adult
KW  - Allografts
KW  - Chronic Disease
KW  - Double-Blind Method
KW  - Female
KW  - Follow-Up Studies
KW  - Glomerular Filtration Rate
KW  - Graft Rejection
KW  - Graft Survival
KW  - HLA Antigens
KW  - Humans
KW  - Immunoglobulins, Intravenous
KW  - Immunologic Factors
KW  - Isoantibodies
KW  - Kidney Failure, Chronic
KW  - Kidney Function Tests
KW  - Kidney Transplantation
KW  - Male
KW  - Middle Aged
KW  - Postoperative Complications
KW  - Prognosis
KW  - Prospective Studies
KW  - Risk Factors
KW  - Rituximab
KW  - Tissue Donors
TI  - Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
TY  - research article
VL  - 18
ER  -